Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Semax
Also known as: ACTH 4-7 PGP, Heptapeptide Semax
Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed in Russia and approved there as a prescription medication for stroke, cognitive disorders, and optic nerve disease. It exhibits nootropic, neuroprotective, and neurogenic properties without the hormonal effects of full-length ACTH. Extensive clinical use in Russia provides a substantial safety record, though Western clinical trials are limited.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 80714-61-0 |
| Molecular Formula | C37H51N9O10S |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
Semax upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, promoting neuronal survival and synaptic plasticity. It modulates serotonergic, dopaminergic, and cholinergic neurotransmission, contributing to its cognitive-enhancing effects. The peptide also exhibits anti-inflammatory actions in the CNS by modulating cytokine expression and reducing oxidative stress.
Dosing Research
Intranasal administration at 200-600 mcg per day divided into 2-3 doses is the standard clinical protocol. Higher doses up to 1200 mcg/day have been used in stroke treatment. Cycles of 10-20 days are typical in Russian clinical practice, with breaks between courses.
Side Effects & Risks
Generally very well tolerated with minimal reported side effects. Nasal irritation may occur with intranasal administration. Rare reports of hair loss have been noted at higher doses, possibly related to melanocortin receptor activity. Does not produce hormonal suppression or adrenal effects despite its ACTH fragment origin.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.